MapLight Therapeutics (MPLT) Other Non Operating Income (2024 - 2026)
MapLight Therapeutics (MPLT) posted Other Non Operating Income of $1.4 million for Q4 2025, up 155.93% sequentially from $531000.0 in Q3 2025, and up 109.4% YoY from $649000.0 in Q4 2024.
MapLight Therapeutics (MPLT) Other Non Operating Income (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Other Non Operating Income for 2 years, with the latest figure at $1.4 million in Q4 2025.
- Quarterly Other Non Operating Income rose 109.4% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (changed N/A YoY) and the FY2025 annual result came in at $2.4 million, up 30.57% from the prior year.
- Other Non Operating Income advanced to $1.4 million in Q4 2025 per MPLT's latest filing, from $531000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $1.4 million in Q4 2025 and troughed at $531000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | 531,000.00 |
| Dec 31, 2024 | 649,000.00 |
| Sep 30, 2024 | 797,000.00 |